What is Methocarbamol Used For? A Comprehensive Guide

Methocarbamol is a medication primarily used to relieve acute musculoskeletal pain and discomfort. Classified as a skeletal muscle relaxant, it plays a crucial role in managing muscle spasms and associated pain. This detailed guide aims to provide an in-depth understanding of methocarbamol, covering its uses, mechanism of action, dosage, potential side effects, and important considerations for its use. Healthcare professionals and patients seeking comprehensive information about methocarbamol and its therapeutic applications will find this resource invaluable for informed decision-making.

Indications for Methocarbamol Use

Methocarbamol is primarily indicated and FDA-approved for the adjunctive treatment of acute musculoskeletal pain conditions. Since its initial FDA approval in 1957, methocarbamol has been a recognized option for alleviating muscle spasms. It is categorized as an anti-spasmodic agent, making it effective in treating involuntary skeletal muscle spasms. This distinguishes it from anti-spastic medications like baclofen and dantrolene, which are designed for spasticity related to upper motor neuron disorders. Other common anti-spasmodic agents include cyclobenzaprine and carisoprodol. While diazepam and tizanidine possess both anti-spastic and anti-spasmodic properties, this discussion will focus specifically on methocarbamol and its applications.

Early research in the late 1950s demonstrated methocarbamol’s effectiveness in treating muscle spasms associated with conditions like herniated intervertebral discs. Studies at the time also highlighted its efficacy in orthopedic conditions, providing relief from post-operative muscle spasms and pain related to both acute and chronic disc herniation. These early findings suggested a promising role for methocarbamol in managing musculoskeletal pain.

FDA-Approved Uses of Methocarbamol

Currently, methocarbamol’s clinical application is largely focused on the short-term relief of acute musculoskeletal pain. Clinical guidelines, such as those from the American College of Physicians, recommend prioritizing non-pharmacological treatments for acute or subacute low back pain. However, when medication is deemed necessary, skeletal muscle relaxants like methocarbamol, alongside nonsteroidal anti-inflammatory drugs (NSAIDs), are considered viable options for pain management.

Off-Label Applications of Methocarbamol

Beyond its FDA-approved uses, methocarbamol has been explored for various off-label applications in pain management. These include:

• Acute and chronic non-specific low-back pain: While not a primary treatment, methocarbamol can be used as part of a multimodal approach.
• Inflammatory arthritis: To alleviate muscle spasms and pain associated with inflammatory joint conditions.
• Fibromyalgia: For managing muscle pain and tenderness in fibromyalgia patients.
• Rib fractures: To reduce muscle spasms and pain following rib fractures.
• Myofascial pain: In the treatment of myofascial pain syndrome, characterized by muscle pain and trigger points.
• Abdominal muscle cramps in cirrhosis: To relieve painful muscle cramps in patients with liver cirrhosis.
• Perioperative care for hip and knee replacements: As part of a pain management strategy in the period surrounding joint replacement surgeries.
• Tizanidine withdrawal: Recent case reports suggest potential use in managing withdrawal symptoms from tizanidine.

It’s important to note that methocarbamol is not effective for treating spasticity or rigidity originating from upper motor neuron injuries. Historically, it was used for tetanus, but benzodiazepines are now the preferred treatment for this condition.

Methocarbamol’s Mechanism of Action

The precise way methocarbamol works is still not fully understood. One theory suggests that muscle spasms are a protective reflex to prevent further injury. However, these spasms can become painful and contribute to a “pain-spasm-pain cycle.” While this cycle is a recognized concept, it lacks robust confirmation from clinical and electrophysiologic studies.

Methocarbamol, like other skeletal muscle relaxants, was developed based on animal studies showing a reduction in muscle tone without significant impact on motor activity. It’s generally believed that methocarbamol’s muscle relaxant effects stem from a generalized depression of the central nervous system. Another proposed mechanism involves anticholinergic inhibition of the midbrain reticular activating system. This inhibition may lead to reduced polysynaptic reflexes and decreased muscle tone, effectively an indirect inhibition at the interneuronal junctions of the spinal cord. Importantly, methocarbamol does not directly affect skeletal muscle contractility, motor nerve fibers, or motor end plates.

Pharmacokinetics of Methocarbamol

Understanding how methocarbamol is processed by the body is crucial for effective and safe use.

• Absorption: Oral methocarbamol begins to act within 30 minutes, reaching peak plasma concentrations in approximately 2 hours. It is well absorbed from the gastrointestinal tract.
• Distribution: Methocarbamol exhibits moderate plasma protein binding, ranging from 46% to 50%.
• Metabolism: The drug is primarily metabolized through dealkylation and hydroxylation pathways, potentially followed by conjugation in the liver.
• Elimination: In healthy individuals, methocarbamol has a plasma clearance rate of 0.20 to 0.80 L/h/kg and a plasma elimination half-life of 1 to 2 hours. It is mainly excreted as inactive metabolites in the urine. The typical dosing interval of every 6 hours is based on these pharmacokinetic properties. Studies in hemodialysis patients show that while renal clearance is reduced, the elimination time is not significantly altered compared to individuals with normal renal function. Similarly, patients with cirrhosis exhibit reduced clearance, but specific dosage adjustments are not typically recommended. A dosage of 500 mg twice daily has been reported to be well-tolerated in cirrhotic patients.

Methocarbamol Administration and Dosage

Methocarbamol is available in various forms and dosages to suit different patient needs and clinical scenarios.

Available Dosage Forms and Strengths

The most common route of administration for methocarbamol is oral. It is commercially available in tablet form in strengths of 500 mg and 750 mg. For situations requiring rapid onset or when oral administration is not feasible, intravenous (IV) and intramuscular (IM) formulations are also available, particularly in post-operative settings.

Adult Dosage Guidelines

For adults, the typical daily oral dosage of methocarbamol ranges from 4 to 6 grams, divided into doses taken every 6 hours. While the maximum recommended daily dose is 6 grams, doses up to 8 grams have been used. However, lower doses are frequently employed in clinical practice. For instance, a common dose in hospitalized patients is 500 mg orally every 8 hours. When using IV or IM administration, a typical dose is 1 gram every 8 hours. The total daily dose should not exceed 3 grams, and it is generally recommended to limit IV/IM use to a maximum of 3 consecutive days.

Dosage Adjustments for Specific Patient Populations

Specific patient populations require careful consideration and potential dosage adjustments when using methocarbamol.

• Renal Impairment: Since methocarbamol metabolites are primarily excreted in urine, caution is advised in patients with renal impairment. The IV formulation is contraindicated in renal impairment due to the polyethylene glycol excipient it contains. Oral methocarbamol should be used cautiously in mild to moderate renal impairment. Extra care is needed when administering methocarbamol to patients undergoing dialysis.
• Hepatic Impairment: Methocarbamol is metabolized in the liver. While manufacturer labels do not provide specific dose adjustments for hepatic impairment, caution is warranted in patients with liver dysfunction.
• Pregnancy: Methocarbamol is classified as a pregnancy category C medication. Case reports have suggested potential fetal and congenital abnormalities in pregnant women exposed to methocarbamol. Therefore, it is generally not recommended for use in pregnant women, especially during early pregnancy, unless the potential benefits clearly outweigh the risks.
• Breastfeeding: The safety of methocarbamol use during breastfeeding is not well-established. Animal studies indicate that methocarbamol can cross the placenta and be excreted in breast milk. Manufacturers recommend caution when administering methocarbamol to breastfeeding women, and it is generally not recommended for women who are breastfeeding or may become pregnant.
• Pediatric Patients: The safety and effectiveness of methocarbamol in children under 16 years of age have not been fully established.
• Older Patients: Skeletal muscle relaxants, including methocarbamol, are listed in the Beers Criteria as medications to be avoided in adults 65 years and older. This is due to an increased risk of injury, including falls, fractures, and cognitive or psychomotor impairment. While the absolute risk increase is small (around 0.2%), the anticholinergic properties of methocarbamol can contribute to sedation, confusion, and polypharmacy risks in older adults.

Adverse Effects of Methocarbamol

While generally considered safe, methocarbamol can cause side effects.

Serious adverse effects listed in the prescribing information include seizures, leukopenia, and cholestatic jaundice. However, reports from LiverTox indicate that methocarbamol has not been definitively linked to liver or kidney injury. Seizures have been reported primarily in patients with a history of epilepsy, particularly after IV administration, and in cases of polysubstance toxicity.

Neurological side effects are the most commonly reported, with sedation being the most frequent, followed by dizziness and headache. Other neurological adverse events include confusion, amnesia, falls, syncope, and double vision (diplopia). Gastrointestinal side effects may include dyspepsia, nausea, vomiting, a metallic taste, and cholestatic jaundice. IV administration can lead to thrombophlebitis and injection site pain, particularly if extravasation of the hypertonic solution occurs. Patients may also experience urine discoloration, which is considered clinically insignificant.

Drug-Drug Interactions and Abuse Potential

Studies have explored the abuse potential of methocarbamol. Animal studies suggest a low abuse potential compared to substances like barbiturates and benzodiazepines. However, some human studies have reported potential for abuse. Despite these concerns, recent pharmacovigilance data has not strongly indicated abuse potential for methocarbamol, although under-reporting of adverse effects remains a possibility.

Caution is advised when prescribing methocarbamol to patients also taking other central nervous system depressants, such as opioids and benzodiazepines, or those with a history of substance use disorders, due to the potential for additive CNS depression.

Contraindications and Precautions

Methocarbamol is contraindicated in certain patient populations and situations.

According to the FDA, methocarbamol should not be used in patients with known hypersensitivity to methocarbamol or any of its excipients. The IV formulation is contraindicated in patients with renal impairment due to the polyethylene glycol excipient, which carries a risk of metabolic acidosis, renal injury, and hyperosmolarity.

Warnings and Precautions

• Myasthenia Gravis: Methocarbamol is contraindicated in patients with myasthenia gravis who are taking acetylcholinesterase inhibitors. This is based on a case report of exacerbated muscle weakness potentially due to methocarbamol’s anticholinergic effects.
• Beers Criteria: As mentioned earlier, methocarbamol is on the Beers Criteria list and should be avoided in older adults (65+) due to increased risks of falls, injuries, and cognitive impairment.
• Drug-Laboratory Interference: Methocarbamol can interfere with urine screening tests for vanillyl mandelic acid (VMA) and 5-hydroxy indole acetic acid (5-HIAA), potentially leading to false results.

Monitoring Methocarbamol Therapy

Routine monitoring for patients taking methocarbamol primarily involves assessing clinical response and watching for potential adverse effects. There is no standard requirement for routine blood chemistry checks or therapeutic drug monitoring. However, closer monitoring is recommended for specific populations at higher risk of toxicity, including patients with cirrhosis, those taking multiple CNS depressants, individuals with renal impairment, patients with substance use disorders, and older adults.

Methocarbamol Overdose and Toxicity

Signs and Symptoms of Overdose

Isolated methocarbamol overdose is generally rare and unlikely to be life-threatening unless multiple drugs are involved. Reported symptoms of overdose may include nausea, sedation, seizures, coma, and in very severe cases, death.

Management of Overdose

There is no specific antidote for methocarbamol overdose. Treatment is primarily supportive, focusing on managing symptoms and maintaining vital functions. Data from poison control centers indicates that intentional overdoses, particularly in adolescents, are more common and may involve co-ingestion of other substances. Common clinical effects observed in overdose cases include drowsiness, rapid heart rate (tachycardia), vomiting, and slurred speech. Treatment often involves intravenous fluids and activated charcoal to limit drug absorption.

Enhancing Healthcare Team Outcomes in Methocarbamol Use

Skeletal muscle relaxants like methocarbamol are frequently prescribed for non-specific musculoskeletal pain. Low back pain, a major indication for methocarbamol, is a leading cause of disability worldwide. Effective management of musculoskeletal pain often requires a biopsychosocial approach, addressing physical, psychological, and social factors contributing to the patient’s condition. Non-pharmacological approaches, such as patient education, activity maintenance, and heat or ice therapy, are typically recommended as first-line treatments. Pharmacological options like methocarbamol may be considered for persistent symptoms as part of a comprehensive treatment plan.

Despite widespread use, with millions of prescriptions written annually, high-quality evidence supporting methocarbamol’s clinical efficacy is somewhat limited. While studies suggest it is more effective than placebo for acute musculoskeletal pain and comparable to other muscle relaxants, much of this evidence comes from older, smaller studies. There is conflicting evidence regarding whether methocarbamol offers additional benefit over NSAIDs alone. Some studies have shown no significant improvement when methocarbamol is added to NSAIDs or other pain relievers for acute low back pain.

However, recent research has explored the comparative safety of combining methocarbamol with opioids. One study indicated that methocarbamol, when used with opioids like oxycodone or tramadol, may be associated with lower injury rates compared to other muscle relaxants like carisoprodol and tizanidine. These findings suggest potential differences in risk profiles among different skeletal muscle relaxants when used in combination with opioids.

Clinicians should exercise caution when prescribing methocarbamol, particularly to older adults and patients at risk of polypharmacy. It’s important to recognize that robust evidence demonstrating superior efficacy of methocarbamol over NSAIDs for acute musculoskeletal pain is lacking. A collaborative interprofessional approach involving physicians, nurse practitioners, physician assistants, nurses, and pharmacists is crucial to optimize patient outcomes. This includes careful patient selection, use of methocarbamol as part of a multimodal treatment strategy, close monitoring for efficacy and adverse effects, and consideration of polypharmacy risks. Further high-quality randomized controlled trials are needed to better define the clinical role and optimal use of methocarbamol in managing musculoskeletal pain.

[Placeholder for image related to musculoskeletal pain or muscle relaxants, if available from original article or a suitable stock image]

Review Questions (Note: Questions are not included in the rewritten article as per instructions)

References

1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jan 30, 2017. Methocarbamol. [PMC free article: PMC547852] [PubMed: 31643609]
2. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM., Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the cochrane collaboration. Spine (Phila Pa 1976). 2003 Sep 01;28(17):1978-92. [PubMed: 12973146]
3. See S, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy. 2008 Feb;28(2):207-13. [PubMed: 18225966]
4. O’DOHERTY DS, SHIELDS CD. Methocarbamol; new agent in treatment of neurological and neuromuscular diseases. J Am Med Assoc. 1958 May 10;167(2):160-3. [PubMed: 13538683]
5. FORSYTH HF. Methocarbamol (robaxin) in orthopedic conditions; preliminary report of one hundred cases. J Am Med Assoc. 1958 May 10;167(2):163-8. [PubMed: 13538684]
6. See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 01;78(3):365-70. [PubMed: 18711953]
7. Qaseem A, Wilt TJ, McLean RM, Forciea MA, Clinical Guidelines Committee of the American College of Physicians. Denberg TD, Barry MJ, Boyd C, Chow RD, Fitterman N, Harris RP, Humphrey LL, Vijan S. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Apr 04;166(7):514-530. [PubMed: 28192789]
8. Richards BL, Whittle SL, van der Heijde DM, Buchbinder R. The efficacy and safety of muscle relaxants in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl. 2012 Sep;90:34-9. [PubMed: 22942327]
9. Beebe FA, Barkin RL, Barkin S. A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am J Ther. 2005 Mar-Apr;12(2):151-71. [PubMed: 15767833]
10. Patanwala AE, Aljuhani O, Kopp BJ, Erstad BL. Methocarbamol use is associated with decreased hospital length of stay in trauma patients with closed rib fractures. Am J Surg. 2017 Oct;214(4):738-742. [PubMed: 28088301]
11. Looke TD, Kluth CT. Effect of preoperative intravenous methocarbamol and intravenous acetaminophen on opioid use after primary total hip and knee replacement. Orthopedics. 2013 Feb;36(2 Suppl):25-32. [PubMed: 23379573]
12. Abd-Elsalam S, Arafa M, Elkadeem M, Elfert A, Soliman S, Elkhalawany W, Badawi R. Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients. Eur J Gastroenterol Hepatol. 2019 Apr;31(4):499-502. [PubMed: 30444744]
13. UTTERBACK RA, TENNEY PH. METHOCARBAMOL IN THE THERAPY OF TETANUS. Arch Neurol. 1963 Nov;9:555-60. [PubMed: 14057687]
14. Escobar Gil T, McGeorge KJ, Jones AJ. A Case of Tizanidine Withdrawal and Road to Recovery. Cureus. 2024 Feb;16(2):e53444. [PMC free article: PMC10909376] [PubMed: 38435197]
15. TRUITT EB, PATTERSON RB. Comparative hemolytic activity of mephenesin, guaiacol glycerol ether and methocarbamol in vitro and in vivo. Proc Soc Exp Biol Med. 1957 Jul;95(3):422-4. [PubMed: 13453457]
16. Elenbaas JK. Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980 Oct;37(10):1313-23. [PubMed: 6999895]
17. Sica DA, Comstock TJ, Davis J, Manning L, Powell R, Melikian A, Wright G. Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol. 1990;39(2):193-4. [PubMed: 2253675]
18. Dent RW, Ervin DK. Relief of acute musculoskeletal symptoms with intravenous methocarbamol (robaxin injectable): a placebo-controlled study. Curr Ther Res Clin Exp. 1976 Nov;20(5):661-5. [PubMed: 825351]
19. LEVENTEN EO, VACCARINO FP. Intravenous methocarbamol in 100 orthopedic patients. Curr Ther Res Clin Exp. 1960 Oct;2:497-500. [PubMed: 13761355]
20. Hall JG, Reed SD. Teratogens associated with congenital contractures in humans and in animals. Teratology. 1982 Apr;25(2):173-91. [PubMed: 7101197]
21. Spence MM, Shin PJ, Lee EA, Gibbs NE. Risk of injury associated with skeletal muscle relaxant use in older adults. Ann Pharmacother. 2013 Jul-Aug;47(7-8):993-8. [PubMed: 23821610]
22. By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. [PubMed: 37139824]
23. Viswanathan S. Urine bag as a modern day matula. ISRN Nephrol. 2013;2013:215690. [PMC free article: PMC4045424] [PubMed: 24959539]
24. Sannerud CA, Ator NA, Griffiths RR. Methocarbamol: evaluation of reinforcing and discriminative stimulus effects. Behav Pharmacol. 1991 Apr;2(2):143-150. [PubMed: 11224058]
25. Gahr M, Freudenmann RW, Eller J, Schönfeldt-Lecuona C. Abuse liability of centrally acting non-opioid analgesics and muscle relaxants–a brief update based on a comparison of pharmacovigilance data and evidence from the literature. Int J Neuropsychopharmacol. 2014 Jun;17(6):957-9. [PubMed: 24552880]
26. Preston KL, Wolf B, Guarino JJ, Griffiths RR. Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. J Pharmacol Exp Ther. 1992 Aug;262(2):707-20. [PubMed: 1501118]
27. Dawwas GK, Hennessy S, Brensinger CM, Acton EK, Bilker WB, Chung S, Dublin S, Horn JR, Manis MM, Miano TA, Oslin DW, Pham Nguyen TP, Soprano SE, Wiebe DJ, Leonard CE. Signals of Muscle Relaxant Drug Interactions Associated with Unintentional Traumatic Injury: A Population-Based Screening Study. CNS Drugs. 2022 Apr;36(4):389-400. [PMC free article: PMC9375100] [PubMed: 35249204]
28. Tayar J, Jabbour G, Saggi SJ. Severe hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam. N Engl J Med. 2002 Apr 18;346(16):1253-4. [PubMed: 11961161]
29. Podrizki A. Methocarbamol and myasthenia gravis. JAMA. 1968 Sep 23;205(13):938. [PubMed: 5695627]
30. Corcuff JB, Chardon L, El Hajji Ridah I, Brossaud J. Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations. Endocr Connect. 2017 Aug;6(6):R87-R98. [PMC free article: PMC5527357] [PubMed: 28566493]
31. Lebby TI, Dugger K, Lipscomb JW, Leikin JB. Skeletal muscle relaxant ingestion. Vet Hum Toxicol. 1990 Apr;32(2):133-5. [PubMed: 2327059]
32. 2023 ACMT Annual Scientific Meeting Abstracts – San Diego, CA. J Med Toxicol. 2023 Mar 23;19(2):63-168. [PMC free article: PMC10035466] [PubMed: 36952114]
33. Dillon C, Paulose-Ram R, Hirsch R, Gu Q. Skeletal muscle relaxant use in the United States: data from the Third National Health and Nutrition Examination Survey (NHANES III). Spine (Phila Pa 1976). 2004 Apr 15;29(8):892-6. [PubMed: 15082991]
34. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-1259. [PMC free article: PMC5605509] [PubMed: 28919117]
35. Hartvigsen J, Hancock MJ, Kongsted A, Louw Q, Ferreira ML, Genevay S, Hoy D, Karppinen J, Pransky G, Sieper J, Smeets RJ, Underwood M., Lancet Low Back Pain Series Working Group. What low back pain is and why we need to pay attention. Lancet. 2018 Jun 09;391(10137):2356-2367. [PubMed: 29573870]
36. Foster NE, Anema JR, Cherkin D, Chou R, Cohen SP, Gross DP, Ferreira PH, Fritz JM, Koes BW, Peul W, Turner JA, Maher CG., Lancet Low Back Pain Series Working Group. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018 Jun 09;391(10137):2368-2383. [PubMed: 29573872]
37. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. [PubMed: 15276195]
38. Friedman BW, Cisewski D, Irizarry E, Davitt M, Solorzano C, Nassery A, Pearlman S, White D, Gallagher EJ. A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain. Ann Emerg Med. 2018 Mar;71(3):348-356.e5. [PMC free article: PMC5820149] [PubMed: 29089169]
39. Chen C, Hennessy S, Brensinger CM, Miano TA, Bilker WB, Dublin S, Chung SP, Horn JR, Tiwari A, Leonard CE. Comparative Risk of Injury with Concurrent Use of Opioids and Skeletal Muscle Relaxants. Clin Pharmacol Ther. 2024 Jul;116(1):117-127. [PMC free article: PMC11180590] [PubMed: 38482733]